Fuchs Endothelial Dystrophy Medication
- Author: Daljit Singh, MBBS, MS, DSc; Chief Editor: Hampton Roy, Sr, MD more...
Patients undergoing keratoplasty may require carbonic anhydrase inhibitors before and after the surgery. They are highly effective in reducing the intraocular pressure (IOP) to desired levels.
Carbonic anhydrase inhibitors
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body, including the eye. Catalyzes a reversible reaction where carbon dioxide becomes hydrated and carbonic acid dehydrated. By slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport, it may inhibit CA in the ciliary processes of the eye. This effect decreases aqueous humor secretion, reducing IOP.
Because of highly predictable effect on IOP. Reduces rate of aqueous humor formation by inhibiting enzyme carbonic anhydrase, which results in decreased IOP. Available in PO and parenteral forms.
These agents are most effective in treating inflammations and preventing and treating graft reactions following keratoplasty operation.
Acting on the nucleus of the cell, the steroids produce certain proteins that are immunosuppressive and prevent the production of inflammatory mediators. By their action on the cell wall, they decrease the release of PG. The net result is suppression of inflammation and immune reaction. These effects are obtained through such diverse mechanisms of action as anti-inflammatory, antiallergenic, antiexudative, antiangiogenic, and antiproliferative. Although they have systemic effects, their main action is exerted at the site of inflammation. Therefore, topical application is useful to prevent immune reaction and inflammation.
Has a short biological life of 12-36 h, therefore, interferes less with physiological processes.
Hypertonicity of sodium chloride is used to treat corneal edema.
Sterile ophthalmic solution and ointment used to draw water out of cornea of the eye.
Nonsteroidal anti-inflammatory agents
The inhibition of prostaglandin synthesis, results in vasoconstriction, a decrease in vascular permeability, leukocytosis, and a decrease on IOP. However, these agents have no significant effect on IOP.
Diclofenac sodium is designated chemically as 2-[(2,6-dichlorophenyl) amino] benzeneacetic acid, monosodium salt, with an empirical formula of C14 H10 Cl2 NO2 NA. One of a series of phenylacetic acids that has demonstrated anti-inflammatory and analgesic properties in pharmacological studies. Believed to inhibit the enzyme cyclooxygenase, which is essential in the biosynthesis of prostaglandins.
Member of the pyrrolo-pyrrole group of NSAIDs. When administered systemically, has demonstrated analgesic, anti-inflammatory, and antipyretic activity. Mechanism of action is believed to be due, in part, to its ability to inhibit prostaglandin biosynthesis.
Instillation of a long-acting cycloplegic agent can relax any ciliary muscle spasm that can cause a deep aching pain and photophobia.
An anticholinergic prepared as a sterile, borate buffered solution for topical ocular use. Prevents muscle of ciliary body, and sphincter muscle of iris, from responding to cholinergic stimulation. Induces mydriasis in 30-60 min and cycloplegia in 25-75 min.
Use has been associated with psychotic reactions and behavior disturbances in pediatric patients.
Lorenzetti DW, Uotila MH, Parikh N, Kaufman HE. Central cornea guttata. Incidence in the general population. Am J Ophthalmol. 1967 Dec. 64(6):1155-8. [Medline].
Hecker LA, McLaren JW, Bachman LA, Patel SV. Anterior keratocyte depletion in fuchs endothelial dystrophy. Arch Ophthalmol. 2011 May. 129(5):555-61. [Medline].
Higa A, Sakai H, Sawaguchi S, et al. Prevalence of and risk factors for cornea guttata in a population-based study in a southwestern island of Japan: the kumejima study. Arch Ophthalmol. 2011 Mar. 129(3):332-6. [Medline].
Cross HE, Maumenee AE, Cantolino SJ. Inheritance of Fuchs' endothelial dystrophy. Arch Ophthalmol. 1971 Mar. 85(3):268-72. [Medline].
Baratz KH, Tosakulwong N, Ryu E, Brown WL, Branham K, Chen W, et al. E2-2 Protein and Fuchs's Corneal Dystrophy. N Engl J Med. 2010 Sep 9. 363(11):1016-24. [Medline].
Laing RA, Leibowitz HM, Oak SS, et al. Endothelial mosaic in Fuchs' dystrophy. A qualitative evaluation with the specular microscope. Arch Ophthalmol. 1981 Jan. 99(1):80-3. [Medline].
Guerra FP, Anshu A, Price MO, Giebel AW, Price FW. Descemet's Membrane Endothelial Keratoplasty Prospective Study of 1-Year Visual Outcomes, Graft Survival, and Endothelial Cell Loss. Ophthalmology. 2011 Dec. 118(12):2368-73. [Medline].
Price MO, Gorovoy M, Benetz BA, et al. Descemet's Stripping Automated Endothelial Keratoplasty Outcomes Compared with Penetrating Keratoplasty from the Cornea Donor Study. Ophthalmology. 2009 Dec 22. [Medline].
Rao SK, Leung CK, Cheung CY, et al. Descemet stripping endothelial keratoplasty: effect of the surgical procedure on corneal optics. Am J Ophthalmol. 2008 Jun. 145(6):991-6. [Medline].
van der Meulen IJ, Patel SV, Lapid-Gortzak R, et al. Quality of vision in patients with fuchs endothelial dystrophy and after descemet stripping endothelial keratoplasty. Arch Ophthalmol. 2011 Dec. 129(12):1537-42. [Medline].
Dirisamer M, van Dijk K, Dapena I, Ham L, Oganes O, Frank LE. Prevention and management of graft detachment in descemet membrane endothelial keratoplasty. Arch Ophthalmol. 2012 Mar. 130(3):280-91. [Medline].
Brady SE, Rapuano CJ, Arentsen JJ, et al. Clinical indications for and procedures associated with penetrating keratoplasty, 1983-1988. Am J Ophthalmol. 1989 Aug 15. 108(2):118-22. [Medline].
Adamis AP, Filatov V, Tripathi BJ, Tripathi RC. Fuchs' endothelial dystrophy of the cornea. Surv Ophthalmol. 1993 Sep-Oct. 38(2):149-68. [Medline].
[Guideline] American Academy of Ophthalmology Refractive Management/Intervention Panel. Refractive errors & refractive surgery. San Francisco (CA): American Academy of Ophthalmology; 2007.
Borboli S, Colby K. Mechanisms of disease: Fuchs' endothelial dystrophy. Ophthalmol Clin North Am. 2002 Mar. 15(1):17-25. [Medline].
Melles GR, Remeijer L, Geerards AJ, Beekhuis WH. The future of lamellar keratoplasty. Curr Opin Ophthalmol. 1999 Aug. 10(4):253-9. [Medline].
Rodrigues MM, Krachmer JH, Hackett J, Gaskins R, Halkias A. Fuchs' corneal dystrophy. A clinicopathologic study of the variation in corneal edema. Ophthalmology. 1986 Jun. 93(6):789-96. [Medline].
Rosenblum P, Stark WJ, Maumenee IH, Hirst LW, Maumenee AE. Hereditary Fuchs' Dystrophy. Am J Ophthalmol. 1980 Oct. 90(4):455-62. [Medline].
Singh D. Ablation pit treatment for corneal decompensation. Ann Ophthalmol (Skokie). 2006. 38(1):21-4. [Medline].
Wilson SE, Bourne WM. Fuchs' dystrophy. Cornea. 1988. 7(1):2-18. [Medline].